Construction has officially commenced on a cutting-edge RNA research and pilot manufacturing facility at Macquarie University, representing a major step forward in New South Wales’ efforts to tackle future health challenges.
With a $96 million investment from the NSW Government, this world-class facility will be the first of its kind in Australia and one of only a few globally, the government said in a media release.
“This facility will drive jobs and investment in this sector, along with delivering potentially life-saving solutions,” said Premier Chris Minns.
He added, “This is a step forward for healthcare in NSW and an opportunity for us to grow important new high-tech companies.”
Set to be located at Macquarie University’s Wallumattagal campus, the facility will be part of the Connect Macquarie Park Innovation District, a hub for medical, health-related organisations, and technology startups.
Once complete, the facility will provide the capability to design and test RNA vaccines and therapeutics, offering NSW sovereign capability in RNA technology.
“This facility helps put us at the front of the queue in the fierce global battle to attract new investment and build new industries,” said Minister for Innovation, Science and Technology Anoulack Chanthivong.
“Nations around the world are crying out for new health solutions, and our state is well positioned to deliver them.”
The facility will include laboratories and production lines, offering capacity to manufacture RNA-based therapeutics for all phases of clinical trials.
RNA technology, which gained prominence during the COVID-19 pandemic, has the potential to treat a wide range of conditions, from cancers to genetic diseases and other viruses.
“It will build on existing NSW Government investments, including the NSW RNA Production & Research Network, the UNSW RNA Institute, and Australia’s first Viral Vector Manufacturing Facility at Westmead Health and Innovation District,” added Minister for Medical Research David Harris.
With completion expected in 2026, the facility will be operated by Aurora Biosynthetics, a subsidiary of Myeloid Therapeutics, and overseen by RNA Australia, a newly formed joint venture between the NSW Government and several universities.
“Macquarie University is proud to host this groundbreaking new facility, which is a significant addition to the thriving medical precinct within the Connect Macquarie Park Innovation District,” said Professor Sakkie Pretorius, deputy vice-chancellor (Research) at Macquarie University.
“RNA research has incredible potential, and we share in RNA Australia’s vision for advancing biomedical science for the benefit of Australia and the world.”
